Skip to main content
 
 
 
 

2021 Annual Report

Expanding The

2021

Expanding The

TO EXPAND is to push boundaries – to go beyond established limits.

The POSSIBLE is what is plausible – able to happen.

The Leukemia & Lymphoma Society (LLS) worked tirelessly in 2021 to expand treatment options and the possibility of cures. And we made progress in every facet of our mission: we broadened the research landscape with innovative approaches, provided a wide range of educational materials, increased support and financial assistance for patients and families, and continued to advocate for accessible treatments for all patients.

2021 was a year of EXPANDING THE POSSIBLE.

Expanding possibilities

Dear Friends,

Dr. Louis J. DeGennaro and Ralph Lawson

For decades, LLS has served as a “change enthusiast,” playing a role in expanding possibilities for nearly every blood cancer patient. Our mission remains unchanged: Cure leukemia, lymphoma, Hodgkin's disease and myeloma, and improve the quality of life of patients and their families. More than ever, we are committed to leveling the playing field in blood cancer research and care and addressing the needs of previously underserved populations to ensure a future of expanded hope for all members of our community.

Among our many 2021 achievements, we:

  • ...initiated first-of-its-kind research on COVID-19 vaccine efficacy— using data submitted from patients serving as “citizen scientists”—to facilitate vaccine decision-making
  • ...promoted a treatment modality that barely existed four years ago and is now creating long remissions in patients on the brink of death
  • ...increased financial assistance for patients and families by 70% over last year
  • ...enhanced efforts to expand equitable access to care— including clinical trials—for all blood cancer patients, making inroads in communities that have been traditionally overlooked
  • ...launched a new program to fund health services research, to ensure enhanced access to blood cancer care and services
  • ...advanced the design of a landmark global master trial that promises to revolutionize pediatric standard of care for acute leukemia
  • ...set records in fundraising despite global pandemic challenges, allowing for reinvestment into ongoing research and patient programs

Of course, for us, the ultimate expansion of possibility will be a world where blood cancer is no longer a death sentence and can be cured. On behalf of the 1.3 million Americans living with—or in remission from—blood cancer, we will not stop until mission impossible turns into mission possible. With your help we will get there.

Louis J. DeGennaro

Louis J. DeGennaro, Ph.D.
President and Chief Executive Officer

Ralph Lawson

Ralph Lawson
Chair of the Board

LLS is driving incredible progress for patients

Download a PDF of our full Annual Report below to read more about our lifesaving efforts this year.

In Gratitude

Thank you for being part of our 2021 story.

Expanding the possibilities for patients and their families could not have happened without you: our donors, volunteers, researchers, healthcare professionals, foundations, partners, sponsors, and philanthropic leaders across the country.

See Our Incredible Supporters

Our Previous Annual Reports

The complete audited financial statements are contained in the annual reports below.

2020

ar2020_thumb

2019

ar2019_thumb

2018

ar2018_thumb

2017

ar2017_thumb

2016

ar2016_thumb

2015

ar2015_thumb

2014

ar2014_thumb

2013

ar2013_thumb

2012

ar2012_thumb

2011

ar2011_thumb

2010

ar2010_thumb

2009

ar2009_thumb

2008

ar2008_thumb

2007

ar2007_thumb

2006

ar2006_thumb

2005

ar2005_thumb

2004

ar2004_thumb

2003

ar2003_thumb

2002

ar2002_thumb

2001

ar2001_thumb

2000

ar2000_thumb